Hepatocellular carcinoma immune landscape and the potential of immunotherapies
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …
Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go
K Wang, C Wang, H Jiang, Y Zhang, W Lin… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …
Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma
X Zheng, X Liu, Y Lei, G Wang, M Liu - Frontiers in oncology, 2022 - frontiersin.org
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated
in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues …
in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues …
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Basic and clinical studies have demonstrated the efficacy of immunotherapy, a technical and
conceptual breakthrough that has revolutionised cancer treatment. Hepatocellular …
conceptual breakthrough that has revolutionised cancer treatment. Hepatocellular …
Glypicans as cancer therapeutic targets
Glypicans are a group of cell-surface glycoproteins in which heparan sulfate (HS)
glycosaminoglycan chains are covalently linked to a protein core. The glypican gene family …
glycosaminoglycan chains are covalently linked to a protein core. The glypican gene family …
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
W Xu, K Liu, M Chen, JY Sun… - … in medical oncology, 2019 - journals.sagepub.com
The introduction of immunotherapies has been a major development in the treatment of
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …
many advanced cancers, including hepatocellular carcinoma (HCC). We are entering a new …
Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics
Background Glioblastoma (GBM) consists of devastating neoplasms with high invasive
capacity, which have been difficult to study in vitro in a human-derived model system …
capacity, which have been difficult to study in vitro in a human-derived model system …
Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy
Z Yang, Y Liu, K Zhao, W **g, L Gao… - … Clinics and Research, 2023 - journals.lww.com
Hepatocellular carcinoma (HCC) is a prevalent and lethal disease, and tumor regression
rarely occurs in advanced HCC patients due to limited effective therapies. Given the …
rarely occurs in advanced HCC patients due to limited effective therapies. Given the …
Role of cell surface proteoglycans in cancer immunotherapy
Over the past few decades, understanding how tumor cells evade the immune system and
their communication with their tumor microenvironment, has been the subject of intense …
their communication with their tumor microenvironment, has been the subject of intense …
On-demand reprogramming of immunosuppressive microenvironment in tumor tissue via multi-regulation of carcinogenic microRNAs and RNAs dependent …
L Chen, W Tang, J Liu, M Zhu, W Mu, X Tang, T Liu… - Biomaterials, 2025 - Elsevier
The frequent immune escape of tumor cells and fluctuating therapeutic efficiency vary with
each individual are two critical issues for immunotherapy against malignant tumor. Herein …
each individual are two critical issues for immunotherapy against malignant tumor. Herein …